2024
A proteome‐wide analysis unveils a core Epstein–Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations
Sarathkumara Y, Xian R, Liu Z, Yu K, Chan J, Kwong Y, Lam T, Liang R, Chiu B, Xu J, Hu W, Ji B, Coghill A, Kelly A, Pfeiffer R, Rothman N, Ambinder R, Hildesheim A, Lan Q, Proietti C, Doolan D. A proteome‐wide analysis unveils a core Epstein–Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations. International Journal Of Cancer 2024, 155: 1476-1486. PMID: 38995124, PMCID: PMC11326961, DOI: 10.1002/ijc.35072.Peer-Reviewed Original ResearchEBV-positive cHLEpstein-Barr virusAntibody signaturesCase-control studyHodgkin lymphomaHumoral immune response to EBVEBV gene expression patternsImmune response to EBVAntibody responseHospital-based case-control studyResponse to EBVEast Asian populationsIgG antibodiesEpstein-Barr virus antibodiesClassical Hodgkin lymphomaAnti-EBV IgG antibodyMatched healthy controlsCHL patientsEBV antibodiesEBV proteinsHealthy controlsCustom protein microarrayPotential biomarkersEthnically diverse populationsAntibodies
2018
Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. The Oncologist 2018, 24: 955-962. PMID: 30568021, PMCID: PMC6656463, DOI: 10.1634/theoncologist.2018-0538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMiddle AgedNivolumabPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesSurvival RateYoung AdultConceptsProgression-free survivalClassical Hodgkin lymphomaPD-1 inhibitorsPD-1iPercent of patientsOverall response rateComplete responseResponse rateSystemic chemotherapyOverall survivalPartial responseSystemic therapyCHL patientsHodgkin's lymphomaClinical trialsRetrospective analysisToxicity profileReal-world settingDeath-1 inhibitor nivolumabMedian progression-free survivalR cHLRefractory classical Hodgkin lymphomaDeath-1 inhibitorsPrior autoimmune diseaseR cHL patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply